Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

Luisa Carbognin; Sara Pilotto; Michele Milella; Vanja Vaccaro; Matteo Brunelli; Anna Caliò; Federica Cuppone; Isabella Sperduti; Diana Giannarelli; Marco Chilosi; Vincenzo Bronte; Aldo Scarpa; Emilio Bria; Giampaolo Tortora

doi:10.1371/journal.pone.0130142

Loading metrics

Open Access

Peer-reviewed

Research Article

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

Luisa Carbognin,

Affiliation Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
⨯
Sara Pilotto,

Affiliation Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
⨯
Michele Milella,

Affiliation Medical Oncology, Regina Elena National Cancer Institute, Roma, Italy
⨯
Vanja Vaccaro,

Affiliation Medical Oncology, Regina Elena National Cancer Institute, Roma, Italy
⨯
Matteo Brunelli,

Affiliation Department of Pathology and Diagnostic, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
⨯
Anna Caliò,

Affiliation Department of Pathology and Diagnostic, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
⨯
Federica Cuppone,

Affiliation Agenzia Italiana del Farmaco (AIFA), Roma, Italy
⨯
Isabella Sperduti,

Affiliation Biostatistics, Regina Elena National Cancer Institute, Roma, Italy
⨯
Diana Giannarelli,

Affiliation Biostatistics, Regina Elena National Cancer Institute, Roma, Italy
⨯
Marco Chilosi,

Affiliation Department of Pathology and Diagnostic, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
⨯
Vincenzo Bronte,

Affiliation Department of Pathology and Diagnostic, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
⨯
Aldo Scarpa,

Affiliations Department of Pathology and Diagnostic, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy, ARC-NET Center for Applied Research on Cancer, Verona, Italy
⨯
Emilio Bria ,

Contributed equally to this work with: Emilio Bria, Giampaolo Tortora

* E-mail: emilio.bria@univr.it

Affiliation Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
⨯
Giampaolo Tortora

Contributed equally to this work with: Emilio Bria, Giampaolo Tortora

Affiliation Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
⨯

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

Luisa Carbognin,
Sara Pilotto,
Michele Milella,
Vanja Vaccaro,
Matteo Brunelli,
Anna Caliò,
Federica Cuppone,
Isabella Sperduti,
Diana Giannarelli,
Marco Chilosi

Published: June 18, 2015
https://doi.org/10.1371/journal.pone.0130142

Reader Comments (1)

Post a new comment on this article

0 Responses

18 Jul 2015
18:43 GMT
Most Recent

Patients with no PD-L1 expression should not be excluded from anti-PD1/PD-L1 based immunotherapy clinical trials Posted by pashtoonkasi on 18 Jul 2015 at 18:43 GMT

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Melanoma
Is the Subject Area "Melanoma" applicable to this article?

Thanks for your feedback.
Genitourinary cancers
Is the Subject Area "Genitourinary cancers" applicable to this article?

Thanks for your feedback.
Bladder cancer
Is the Subject Area "Bladder cancer" applicable to this article?

Thanks for your feedback.
Immune response
Is the Subject Area "Immune response" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Renal cell carcinoma
Is the Subject Area "Renal cell carcinoma" applicable to this article?

Thanks for your feedback.